AI Article Synopsis

  • A study evaluated the impact of anticoagulation therapy on transvalvular gradients and valve haemodynamic deterioration (VHD) in 2,466 patients who underwent transcatheter aortic valve replacement (TAVR).
  • Anticoagulation therapy was associated with a stable mean transvalvular gradient post-TAVR, while patients not on anticoagulants experienced significant increases, and the incidence of VHD was notably lower in the anticoagulation group (0.6% vs 3.7%).
  • VHD was mostly subclinical and did not link to increased risks of all-cause death, cardiovascular death, or stroke, highlighting the need for further studies on systematic anticoagulation post-TAVR.

Article Abstract

Objective: To evaluate the changes in transvalvular gradients and the incidence of valve haemodynamic deterioration (VHD) following transcatheter aortic valve replacement (TAVR), according to use of anticoagulation therapy.

Methods And Results: This multicentre study included 2466 patients (46% men; mean age 81±7 years) who underwent TAVR with echocardiography performed at 12-month follow-up. Anticoagulation therapy was used in 707 patients (28.7%) following TAVR (AC group). A total of 663 patients received vitamin K antagonists, and 44 patients received direct oral anticoagulants. A propensity score matching analysis was performed to adjust for intergroup (AC vs non-AC post-TAVR) differences. A total of 622 patients per group were included in the propensity-matched analysis. VHD was defined as a ≥10 mm Hg increase in the mean transprosthetic gradient at follow-up (vs hospital discharge). The mean clinical follow-up was 29±18 months. The mean transvalvular gradient significantly increased at follow-up in the non-AC group within the global cohort (P=0.003), whereas it remained stable over time in the AC group (P=0.323). The incidence of VHD was significantly lower in the AC group (0.6%) compared with the non-AC group (3.7%, P<0.001), and these significant differences remained within the propensity-matched populations (0.6% vs 3.9% in the AC and non-AC groups, respectively, P<0.001). The occurrence of VHD did not associate with an increased risk of all-cause death (P=0.468), cardiovascular death (P=0.539) or stroke (P=0.170) at follow-up.

Conclusions: The lack of anticoagulation therapy post-TAVR was associated with significant increments in transvalvular gradients and a greater risk of VHD. VHD was subclinical in most cases and did not associate with major adverse clinical events. Future randomised trials are needed to determine if systematic anticoagulation therapy post-TAVR would reduce the incidence of VHD.

Download full-text PDF

Source
http://dx.doi.org/10.1136/heartjnl-2017-312514DOI Listing

Publication Analysis

Top Keywords

anticoagulation therapy
8
valve haemodynamic
8
haemodynamic deterioration
8
transcatheter aortic
8
aortic valve
8
valve replacement
8
patients received
8
non-ac group
8
group
6
patients
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!